AAV - Production platforms for gene therapy development
Licensable AAV production platforms
Efficient, scalable and cost-effective platforms for vector engineering
OXGENE helps solve the challenge of scalable manufacture for gene therapy.
Our GMP-compliant solutions accelerate the development of novel therapeutics, ensuring consistent quality of rAAV vectors and minimising risk during the product development lifecycle.
Resource updated on 18/2/2021
Download the resource to continue reading.